Myoinositol Effect on Asprosin Levels
Condition: Pregnancy Related
MeSH terms: Marfan Syndrome
Study type: Interventional

Summary: 
      Asprosin is aa adipokine associated with glucose and insulin metabolism. Insulin and glucose
      metabolism change during pregnancy and studies examining asprosin levels during pregnancy are
      increasing rapidly. Considering the beneficial effects of myo-inositol to support the
      physiological pregnancy, recovering and pre-venting adverse maternal and fetal outcomes, we
      aimed to evaluate the effects of its supplementation on serum asprosin levels in pregnant
      women.
    

Detailed description: 
      Asprosin, which was first mentioned in an article in 2016, is a pluripotent adipokine that is
      a product of profibrillin and its main source is white adipose tissue. It has been observed
      that asprosin is associated with glucose metabolism, and its plasma level increases after
      overnight fasting and decreases after feeding. After the demonstration that asprosin
      increases glucose secretion from the liver, subsequent studies have determined that its serum
      levels are increased in type 2 diabetes, human and mouse models with insulin resistance,
      positively correlates with obesity, and high asprosin levels have been associated with
      metabolic syndrome.

      Pregnancy is known to be a diabetogenic process and insulin resistance is increased during
      gestation. Also, it is known that there is an increase in the production of adipokines during
      pregnancy. There are a limited number of studies in pregnancy on asprosin which is known to
      be produced also from the placenta. Studies examining asprosin in pregnancy in the literature
      mostly examined the relationship between gestational diabetes (GDM). GDM, which is defined as
      glucose intolerance with variable severity of hyperglycemia that occurs during pregnancy, is
      the most common metabolic disorder during pregnancy and its prevalence varies between 5-10%
      according to the patient population examined and the diagnostic test used. In addition, these
      patients also have impaired insulin secretion. Recently, it has been shown that asprosin
      levels are increased in the blood of patients with GDM.

      Inositol is a polyol structure molecule belonging to the vitamin B complex, which can be
      produced in many organs in the body and can also be taken from the outside with food.
      Myo-inositol (MI) is one of the most important of the 9 inositol stereoisomers, and this
      molecule has been studied many times in the literature in recent years. In the literature, it
      is stated that inositol supplementation started in the early weeks of pregnancy prevents GDM
      onset, especially in women in the risk group for developing GDM like obesity, polycystic
      ovary syndrome, etc.. MI, which is an intracellular second messenger and has insulin-like
      effects on glucose metabolism, also reduces insulin resistance.

      Based on these data in the literature, it can be thought that altered serum asprosin levels
      during pregnancy may play a role in the pathogenesis of GDM. In addition, it can be suggested
      that MI, which have proven effects on glucose metabolism, may have an effect on serum levels
      of asprosin, which is considered a new insulin resistance marker. In this study, we aimed to
      examine the effect of the MI on serum asprosin levels of women, which was started in the
      early stages of pregnancy.
    

Intervention name(s): myoinositol and folic acid; folic acid
Intervention type(s): Drug; Drug
Intervention description(s): The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test); The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Other intervention name(s): inofolic, ITF company; folidoce, ITF company
Intervention MeSH terms: Folic Acid; Vitamin B Complex; Inositol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: pregnancy; myoinositol; asprosin